Â鶹ӳ»­

Education session
1¨C2:15 p.m. | E350

Navigating gastrointestinal toxicities: Timing, severity and management
1:15¨C1:30 p.m.
Presenter:

Panel question and answer
1:45¨C2:15 p.m.
Panelist:

Rapid oral abstract session
1¨C2:30 p.m. | E450a

Abstract 7017: Outcomes of LymphoMAP archetypes in untreated diffuse large B-cell lymphoma from the POLARIX trial
2:12¨C2:18 p.m.
Presenter: R. Andrew Harkin, M.D.

Panel question and answer
2:12¨C2:30 p.m.
Panelist: R. Andrew Harkin, M.D.

Oral abstract session
1¨C4 p.m. | Hall D2

Abstract LBA8500: Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational Phase 3 randomized study (WU-KONG28)
1¨C1:12 p.m.
Presenter:

Panel question and answer
1:48¨C2 p.m.
Panelist:

Discussion of abstract LBA8507
3:36¨C3:48 p.m.
Discussant:

Panel question and answer
3:48¨C4 p.m.
Panelist:

Education session
2:45¨C4:15 p.m. | Hall D1

Zongertinib and sevabertinib for nonsquamous non-small cell lung cancer
3:05¨C3:15 p.m.
Presenter:

Panel question and answer
3:15¨C3:35 p.m.
Panelist:

Rapid oral abstract session
2:45¨C4:15 p.m. | E350

Abstract 1516: Addressing geographic disparities in cancer care: An examination of the contributions of international medical graduates (IMGs)
3:15¨C3:21 p.m.
Presenter: Nazli Dizman, M.D.

Panel question and answer
3:33¨C3:45 p.m.
Panelist: Nazli Dizman, M.D.

Rapid oral abstract session
4:30¨C6 p.m. | S504

Abstract 10006: Primary breast malignancies in adolescents and young adults: The UT MD Anderson experience
4:30¨C4:36 p.m.
Presenter: Samantha Catueno, M.D.

Panel question and answer
4:42¨C4:57 p.m.
Panelist: Samantha Catueno, M.D.

Case-based panel
8¨C9 a.m. | S100a

Chair/Moderator:

Clinical science symposium
8¨C9:30 a.m. | Arie Crown Theater

Abstract 8510: First-line (1L) divarasib plus pembrolizumab (pembro) in advanced or metastatic KRAS G12C+ non-small cell lung cancer (NSCLC): Results from the Krascendo-170 study
8:36¨C8:48 a.m.
Presenter:

Panel question and answer
9:12¨C9:30 a.m.
Panelist:

Rapid oral abstract session
8¨C9:30 a.m. | E451

Abstract 2518: Phase 1 study of NTX1088, a first-in-class anti-PVR monoclonal antibody, as monotherapy and combined with pembrolizumab, in patients with advanced solid malignancies
9¨C9:06 a.m.
Presenter:

Panel question and answer
9:12¨C9:24 a.m.
Panelist:

Rapid oral abstract session
1:15¨C2:45 p.m. | Hall D2

Abstract 8515: Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1 and/or KRAS mutations (mut): Interim analysis (IA) of the Phase 2b TRITON study
1:45¨C1:51 p.m.
Presenter:

Abstract 8516: A Phase 1/2 study of TSN1611, a highly selective oral KRAS G12D inhibitor, in solid tumors: Efficacy and safety in KRAS G12D-mutated NSCLC patients
1:51¨C1:57 p.m.
Presenter:

Panel question and answer
1:57¨C2:09 p.m.
Panelist:
Panelist: 

Rapid oral abstract session
1:15¨C2:45 p.m. | E450a

Abstract 6513: Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+BCP-ALL)
1:51¨C1:57 p.m.
Presenter:

Abstract 6514: Updated results of the chemotherapy-free regimen of blinatumomab and ponatinib in patients with newly diagnosed Philadelphia-positive B-cell acute lymphoblastic leukemia
1:57¨C2:03 p.m.
Presenter: Lewis Fady Nasr, M.D.

Panel question and answer
2:03¨C2:15 p.m.
Panelist: 
Panelist: Lewis Fady Nasr, M.D.

Abstract 6515: Long-term outcomes with addition of inotuzumab ozogamicin to HCVAD and sequential blinatumomab in adults with newly diagnosed B-ALL
2:15¨C2:21 p.m.
Presenter: Lewis Fady Nasr, M.D.

Abstract 6516: The impact of MRD and post-remission strategies on outcomes following dose-dense mini-hyper-CVD inotuzumab and blinatumomab in relapsed B-cell acute lymphoblastic leukemia
2:21¨C2:27 p.m.
Presenter: Hannah Goulart, M.D.

Panel question and answer
2:33¨C2:45 p.m.
Panelist: Lewis Fady Nasr, M.D.
Panelist: Hannah Goulart, M.D.

Oral abstract session
1:15¨C4:15 p.m. | Hall B1

Co-chair/Moderator:

Case-based panel
3¨C4:15 p.m. | Hall D2

Surgical oncologist perspective
Panelist:

Oral abstract session
3¨C6 p.m. | S100a

Abstract LBA2000: Final results of a randomized, controlled, Phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases
3¨C3:12 p.m.
Presenter:

Panel question and answer
4¨C4:12 p.m.
Panelist:

Oral abstract session
3¨C6 p.m. | Hall D1

Abstract 5000: Clinico-transcriptomic risk stratification to guide abiraterone treatment intensification in high-risk prostate cancer: A combined analysis of NRG/RTOG 9202, 9413, 9902 and 0521
3¨C3:12 p.m.
Presenter: Krishnan Patel, M.D.

Panel question and answer
4¨C4:12 p.m.
Panelist: Krishnan Patel, M.D.

Oral abstract session
3¨C6 p.m. | Arie Crown Theater

Abstract 7002: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma: Interim futility analysis
3:24¨C3:36 p.m
Presenter:

Panel question and answer
3:48¨C4 p.m.
Panelist:

Oral abstract session
8¨C11 a.m. | S100a

Co-chair/moderator:

Oral abstract session
8¨C11 a.m. | Hall D2

Abstract LBA3503: BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC)
9¨C9:12 a.m.
Presenter:

Abstract 3504: SWOG S2107: Randomized Phase 2 trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAF^V600E metastatic colorectal cancer (mCRC)
9:12¨C9:24 a.m.
Presenter:

Panel question and answer
9:48¨C10 a.m.
Panelist:
Panelist:

Education session
9:45¨C11 a.m. | E451

Antibody-drug conjugates and other new agents in endometrial cancer: Overcoming resistance
10¨C10:15 p.m.
Presenter:

Panel question and answer
10:30¨C11 a.m.
Panelist:

Rapid oral abstract session
9:45¨C11:15 a.m. | E450a

Co-chair/moderator:

Oral abstract session
8¨C11 a.m. | S100bc

Abstract 11008: Impact of dedicated care coordination on access to multidimensional support services in young-onset colorectal cancer: A pragmatic trial
10:24¨C10:36 a.m.
Presenter:

Panel question and answer
10:48¨C11 a.m.
Panelist:

Rapid oral abstract session
9:45¨C11:15 a.m. | S403

Abstract 10517: Intralesional PD-1 blockade for oral cancer prevention: First-in-class Phase 1 trial
10:57¨C11:03 a.m.
Presenter:

Panel question and answer
11:03¨C11:15 a.m.
Panelist:

Award lecture
11:30¨C12:15 a.m. | S403

ASCO-American Cancer Society Cancer Prevention Award Recipient
11:50 a.m.¨C12:10 p.m.
Recipient/presenter:

Education session
4:30¨C5:45 p.m. | S100bc

Reconstruction in context: Integrating surgery, radiation and systemic therapy
5¨C5:15 p.m.
Presenter:

Panel question and answer
5:15¨C5:45 p.m.
Panelist:

Rapid oral abstract session
4:30¨C6 p.m. | S504

Abstract 11516: Phase 1 study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma
5:06¨C5:12 p.m.
Presenter:

Panel question and answer
5:18¨C5:30 p.m.
Panelist:

Rapid oral abstract session
4:30¨C6 p.m. | Arie Crown Theater

Abstract 8015: Impact of neoadjuvant durvalumab (D) on tumor microenvironment (TME) features and their association with event-free survival (EFS) in patients with resectable NSCLC (R-NSCLC) from the Phase 3 AEGEAN trial
5:30¨C5:36 p.m.
Presenter:

Panel question and answer
5:48¨C6 p.m.
Panelist:

Case-based session
8¨C9 a.m. | E450a

Radiation Oncologist and Access Perspective
Panelist:

Rapid oral abstract session
8¨C9:30 a.m. | Hall D2

Abstract 4515: Phase 2 study of frontline gemcitabine, 5-fluorouracil/leucovorin and cisplatin (GemFLP) in advanced urachal and non-urachal urinary tract adenocarcinoma
8:06¨C8:12 a.m.
Presenter: Emanuele Crupi, M.D.

Panel question and answer
8:18¨C8:30 a.m.
Panelist: Emanuele Crupi, M.D.

Abstract 4520: Prospective clinical activity and preclinical basis of panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma (RMC): A collaborative multi-institutional study
9:06¨C9:12 a.m.
Presenter:

Panel question and answer
9:18¨C9:30 a.m.
Panelist:

Clinical science symposium
8¨C9:30 a.m. | E450b

Abstract 6009: Clinical activity of REM-422, a MYB mRNA degrader, in recurrent/metastatic adenoid cystic carcinoma: Final results from the Phase 1/2 dose-escalation cohort
8:12¨C8:24 a.m.
Presenter:

Panel question and answer
9:12¨C9:30 a.m.
Panelist:

Clinical science symposium
8¨C9:30 a.m. | S504

Abstract 11509: Spatial RNA-protein profiling of antibody-drug conjugate (ADC) targets in leiomyosarcoma (LMS)
8:12¨C8:24 a.m.
Presenter:

Abstract 11511: Overall survival analysis of a heavily pretreated population of patients with bone sarcomas treated with mecbotamab vedotin, a conditionally binding ADC targeting AXL
8:48¨C9 a.m.
Presenter:

Panel question and answer
9:12¨C9:30 a.m.
Panelist:
Panelist:

Clinical science symposium
9:45¨C11:15 a.m. | Hall D1

Co-chair:

Harnessing artificial intelligence for more personalized and accessible cancer care: Are we there yet?
10:45¨C10:57 a.m.
Discussant of abstracts 106, 107, 108, 109:

Panel question and answer
10:57¨C11:15 a.m.
Moderator and panelist:

Award lecture
11:30 a.m.¨C12:15 p.m. | Hall D2

Chair:

Gianni Bonadonna Breast Cancer Award Recipient
11:50 a.m.¨C12:10 p.m.
Recipient/Presenter:

Oral abstract session
11:30 a.m.¨C2:30 p.m. | S100bc

Abstract 12005: A Phase 3 placebo controlled randomized controlled trial using combination therapy for treatment-related fatigue in patients with prostate cancer
12:54¨C1:06 p.m.
Presenter:

Panel question and answer
1:18¨C1:30 p.m.
Panelist:

Education session
1:15¨C2:30 p.m. | E451

Treatment beyond first-line chemoimmunotherapy for metastatic anal cancer
1:30¨C1:45 p.m.
Presenter:

Panel question and answer
2¨C2:30 p.m.
Panelist:

Education session
1:15¨C2:30 p.m. | S100a

The artificial intelligence advantage ¡ª Easing the path from discovery to delivery
1:45¨C2 p.m.
Presenter:

Panel question and answer
2¨C2:30 p.m.
Panelist:

3¨C4:15 p.m. | S504

Chair:

Treatment of relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
3:30¨C3:45 p.m.
Presenter:

Panel question and answer
3:45¨C4:15 p.m.
Moderator:

Oral abstract session
1:15¨C4:15 p.m. | Hall D1

Abstract 8008: ABBV-706 as monotherapy and in combination with budigalimab in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC)
3:39¨C3:51 p.m.
Presenter:

Panel question and answer
4:03¨C4:15 p.m.
Panelist:

Oral abstract session
3¨C6 p.m. | S100bc

Abstract 1505: Impact of remote symptom monitoring on acute care utilization in Phase 1 cancer patients: Secondary analysis of a randomized clinical trial
4:24¨C4:36 p.m.
Presenter: Jack Stover, M.D.

Panel question and answer
4:48¨C5 p.m.
Panelist: Jack Stover, M.D.

Education session
4:45¨C6 p.m. | S100a

Perioperative immunotherapy: Is more always better?
4:45¨C4:57 p.m.
Presenter:

Panel question and answer
5:21¨C5:48 p.m.
Panelist:

Special session
8¨C9:15 a.m. | Hall D1

Chair:

Rapid oral abstract session
9:45¨C11:15 a.m. | E451

Abstract 3014: First-in-human trial of BH-30643, a novel macrocyclic, non-covalent, mutant-selective OMNI-EGFR inhibitor, in EGFR-mutant (EGFRm) NSCLC
10:21¨C10:27 a.m.
Presenter:

Panel question and answer
10:27¨C10:39 a.m.
Panelist:

Oral abstract session
9:45 a.m.¨C12:45 p.m. | Hall D1

Co-chair/moderator:

Oral abstract session
9:45 a.m.¨C12:45 p.m. | S100a

Abstract 6502: A Phase 2 trial of tagraxofusp, hyper-CVAD and venetoclax for patients with newly diagnosed or relapsed/refractory BPDCN
10:09¨C10:21 a.m.
Presenter:

Panel question and answer
10:33¨C10:45 a.m.
Panelist:

Abstract 6503: A multicenter Phase 1b/2 trial of azacitidine, venetoclax and ivosidenib in IDH1-mutated acute myeloid leukemia (AML)
10:45¨C10:57 a.m.
Presenter: Jennifer Marvin-Peek, M.D.

Abstract 6504: Quizartinib in combination with decitabine and venetoclax for newly diagnosed and relapsed/refractory FLT3-mutated AML
10:57¨C11:09 a.m.
Presenter:

Abstract 6504: Revumenib as maintenance for AML following allogeneic stem cell transplantation
11:09¨C11:21 a.m.
Presenter: Hannah Goulart, M.D.

Panel question and answer
11:33¨C11:45 a.m.
Panelist: Jennifer Marvin-Peek, M.D.
Panelist:
Panelist: Hannah Goulart, M.D.

Education session
11:30 a.m.¨C12:45 p.m. | E451

Chair:

Going beyond immunotherapy for the treatment of microsatellite instable tumors through the development of Werner helicase inhibitors
11:30¨C11:45 a.m.
Presenter:

Panel question and answer
12:15¨C12:45 p.m.
Moderator:

9 a.m.¨Cnoon

Abstract 1549 (Poster Board 299): Impact of a centralized APP-led peer-to-peer program on patient access, provider burden and institutional revenue
Presenter: Sarah Bottomley, D.N.P.

Abstract 1593 (Poster Board 511): Understanding barriers to the clinical breast exam in Telangana, India: A survey study of participants and non-participants in underserved rural and urban areas
Presenter:

Abstract 1597 (Poster Board 515): Leukemia mortality in Latin America and the United States: A population-based analysis
Presenter: Leticia Campoverde, M.D.

Abstract 1640 (Poster Board 558): Sociodemographic variation in live birth incidence and access to assisted reproductive services among female cancer patients in the United States
Presenter: Isabel Beshar, M.D.

Abstract 3519 (Poster Board 273): TROP2 as an actionable biomarker for anal cancer
Presenter: Mir Lim, M.D.

Abstract 3572 (Poster Board 339): Circulating tumor DNA (ctDNA) tumor fraction (TF) dynamics to refine progression-free survival and radiographic response during anti-EGFR rechallenge in metastatic colorectal cancer
Presenter: Guglielmo Vetere, M.D.

Abstract 3585 (Poster Board 352): Circulating tumor DNA for characterizing intratumor heterogeneity and outcomes in metastatic colorectal cancer
Presenter: Cynthia Yeung, M.D.

Abstract 3609 (Poster Board 376): Refining clinical trial eligibility for minimal residual disease in patients with colorectal cancer: The UT MD Anderson INTERCEPT experience
Presenter: Soumya Shekhar, M.D.

Abstract 3615 (Poster Board 382): Association between circulating tumor DNA and local tumor regrowth and distant metastasis during nonoperative management in Stage 1-3 rectal cancer
Presenter: Kentaro Ochiai, M.D., Ph.D.

Abstract 3623 (Poster Board 390): Stage-specific circulating tumor DNA (ctDNA) positivity and minimal residual disease (MRD) decision making in colorectal cancer (CRC) in the prospective INTERCEPT program
Presenter: Emerik Oesterlund, M.D., Ph.D.

Abstract 3671 (Poster Board 438): Use of KMT2 family mutations to define a distinct epithelial-high, stromal-depleted and interferon-active gene expression state in colorectal cancer
Presenter: Songwit Payapwattanawong, M.D.

Abstract TPS3683 (Poster Board 444b): INCA033890-303: A randomized, double-blind, Phase 3 study of FOLFOX and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite-stable colorectal cancer
Presenter:

Abstract TPS3685 (Poster Board 445b): NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA)
Presenter:

Abstract TPS3688 (Poster Board 447a): A Phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA-positive colorectal cancer
Presenter:

Abstract 4124 (Poster Board 107): Beyond fibroblast growth factor receptor 2 (FGFR2) fusions: Mutations and amplifications in intrahepatic cholangiocarcinoma
Presenter: Kimana Quentin, M.B.Ch.B.

Abstract 4128 (Poster Board 111): Real-world outcomes of microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) biliary tract cancers (BTC)
Presenter:

Abstract 4146 (Poster Board 129): Transcriptomic profiling in advanced hepatocellular carcinoma to identify biomarkers for immunotherapy response and mechanisms of acquired resistance
Presenter:

Abstract 4147 (Poster Board 130): Comprehensive genomic profiling to identify molecular determinants of efficacy of IDH1 inhibition in intrahepatic cholangiocarcinoma
Presenter:

1:30¨C4:30 p.m.

Abstract 3081 (Poster Board 218): First data disclosure from the first-in-human Phase 1/2 trial of SMP-3124LP, the first investigational pegylated liposome CHK1 inhibitor, in patients with selected advanced solid tumors
Presenter:

Abstract 3141 (Poster Board 278): A Phase 1/2 study of ATR inhibitor berzosertib plus immune checkpoint inhibitor avelumab in patients with advanced cancers with DNA damage response (DDR) gene alterations: Tumor microenvironment-mediated pathways of resistance from correlative data
Presenter:

Abstract 3149 (Poster Board 286): Clinical outcomes of patients with cell cycle alterations by treatment type: The UT MD Anderson IMPACT 2 study
Presenter: Abhijit Chakraborty, Ph.D.

Abstract 3150 (Poster Board 287): Clinical outcomes of patients with PI3K pathway alterations by treatment type: The UT MD Anderson IMPACT 2 study
Presenter:

Abstract 3151 (Poster Board 288): Clinical outcomes of patients with RTK-RAS pathway alterations by treatment type: The UT MD Anderson IMPACT 2 study
Presenter: Mehmet Baysal, M.D.

Abstract 3152 (Poster Board 289): Clinical outcomes of patients with TP53 pathway alterations by treatment type: The UT MD Anderson IMPACT 2 study
Presenter: Jacopo Venturini, M.D.

Abstract TPS3160 (Poster Board 294b): BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 ¡Á VEGF bsAb) in patients with advanced solid tumors
Presenter:

Abstract TPS3162 (Poster Board 295b): Phase 1/2 study of CLIO-8221, a HER2-targeted, dual-payload exatecan and ATR inhibitor antibody-drug conjugate (ADC) in patients with advanced HER2-expressing solid tumors
Presenter:

Abstract TPS3170 (Poster Board 299b): Phase 1/2 study of the novel Werner helicase inhibitor EIK1005 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including MSI-H or dMMR tumors
Presenter:

Abstract 2550 (Poster Board 340): Anitocabtagene autoleucel (anito-cel) clinical trial manufacturing experience in patients with relapsed/refractory (RR) or newly diagnosed (ND) multiple myeloma (MM)
Presenter:

Abstract TPS2676 (Poster Board 460b): Biomarker study of BND-22 in combination with cemiplimab in solid tumors.
Presenter: Mohamaed Derbala, M.D.

Abstract TPS2681 (Poster Board 463a): Updated design of INVOKE: A Phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors
Presenter:

Abstract TPS2690 (Poster Board 467b): Cohort expansion of a Phase 1 study of PLN-101095, a first-in-class dual ¦Áv¦Â8/¦Áv¦Â1integrin inhibitor, in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI)
Presenter:

Abstract 6069 (Poster Board 526): Circulating HPV DNA for early detection of minimal residual disease after definitive therapy in oropharyngeal cancer: A Phase 2 biomarker-driven study
Presenter:

Abstract 6080 (Poster Board 537): A Phase 3, randomized, double-arm, open-label controlled study of ASP-1929 photoimmunotherapy (PIT) versus physician¡¯s choice of standard of care (SOC) for patients with locoregional, recurrent head and neck squamous cell carcinoma
Presenter:

Abstract 6117 (Poster Board 574): Palliative neck radiation therapy (RT) in combination with lenvatinib/pembrolizumab (L/P) in BRAF wild-type anaplastic thyroid cancer (BRAF-WT ATC)
Presenter: Anna Lawless, M.B.B.S.

Abstract 6118 (Poster Board 575): Detection, quantification and subtyping of adenoid cystic carcinoma (ACC) using methylation from liquid biopsies
Presenter: Felippe Lazar Neto, M.D., Ph.D.

Abstract 6119 (Poster Board 576): Window of opportunity study of the Notch inhibitor AL101 in Notch1 activated adenoid cystic carcinoma (AAC): Biological effects and biomarker correlates
Presenter: Daniel McGrail, Ph.D.

Abstract TPS6129 (Poster Board 584a): A multicenter, randomized, double-blind, Phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of HPV-negative, PD-L1-positive, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): FORTIFI-HN01
Presenter:

Abstract TPS6136 (Poster Board 587b): Neoadjuvant cemiplimab plus cetuximab prior to salvage surgery for recurrent oral cavity squamous cell carcinoma
Presenter:

Abstract TPS6138 (Poster Board 588b): NRG-HN006: Randomized Phase 2/3 trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer
Presenter:

Abstract 12102 (Poster Board 85): COMFORT Survey: A comparison of the comfort level of hematologic and solid tumor oncology specialists with serious illness conversations
Presenter:

Abstract 12105 (Poster Board 88): Standardized birth rates and access to assisted reproductive technology among female cancer patients in the United States
Presenter: Isabel Beshar, M.D.

Abstract 12157 (Poster Board 140): Major adverse cardiovascular events among prostate cancer patients in the VA, stratified by HIV status and androgen deprivation therapy
Presenter:

9 a.m.¨C12 p.m.

Abstract 5029 (Poster Board 124): Integrated clinical and genomic analysis of mediastinal germ cell tumors (GCT) with somatic transformation (SM): A multi-institutional cohort study
Presenter: Zachariah Thomas, M.B.B.S.

Abstract 5065 (Poster Board 160): Early chemo-induced TME alterations as a predictor of response to PD-1 blockade in AVPC: Single-cell data from C3NIRA
Presenter: Anthos Christofides, M.D.

Abstract TPS5138 (Poster Board 229b): A Phase 2 clinical trial of ivonescimab (VEGFxPD-1 bispecific antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter:

Abstract 8557 (Poster Board 347): Race-associated clinicogenomic predictors in non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Nirosha Perera King, M.D.

Abstract 8629 (Poster Board 419): Patient-reported outcomes (PROs) and health-related quality of life (HRQoL) with taletrectinib in advanced ROS1+ non-small cell lung cancer (NSCLC) from the TRUST-II study
Presenter:

Abstract 8641 (Poster Board 431): A Phase 2 multicenter, open-label, parallel cohort study to evaluate the efficacy, safety and pharmacokinetic profile of ABN401 in patients with advanced solid tumors harboring c-MET dysregulation
Presenter:

Abstract TPS8675 (Poster Board 457a): ALPACCA: Phase 3 trial of firmonertinib vs investigator¡¯s choice of EGFR inhibitor as first-line treatment for locally advanced or metastatic NSCLC with EGFR P-loop and alpha c-helix compressing (PACC) uncommon mutations (FURMO-006)
Presenter:

Abstract 9530 (Poster Board 246): Long-term efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 5-year follow-up data
Presenter:

Abstract 9532 (Poster Board 248): Nivolumab + relatlimab (NIVO + RELA) in advanced melanoma: 5-year update of RELATIVITY-047
Presenter:

Abstract 9575 (Poster Board 291): Microbiome-derived bile acids and association with dietary fiber intake to anti-tumor responses in patients with melanoma receiving immune checkpoint blockade (ICB)
Presenter: Nazli Dizman, M.D.

Abstract TPS9603 (Poster Board 483b): Phase 1/2a dose finding study of triplet regimen of relatlimab (RELA) ipilimumab (IPI) and nivolumab (NIVO) in first-line therapy of metastatic melanoma (MM) (TRINITY)
Presenter: Elizabeth Burton, Ph.D.

Abstract TPS9615 (Poster Board 489b): Phase 2 study of ivonescimab in patients with cutaneous squamous cell carcinoma
Presenter:

Abstract 4530 (Poster Board 9): Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and liver metastasis: Subgroup analysis of the Phase 3 CheckMate-9ER trial
Presenter:

Abstract 4532 (Poster Board 11): Emotional health concerns due to kidney cancer (KC) and unmet needs in patient support: Results from the International Kidney Cancer Coalition (IKCC) Global Patient Survey (GPS)
Presenter:

Abstract 4538 (Poster Board 17): Body composition and quality of life (QOL) with lenvatinib + everolimus (len + eve) versus cabozantinib (cabo) in metastatic clear cell renal cell carcinoma (ccRCC) after PD-1 inhibitor progression: Results from the randomized Phase 2 LenCabo trial
Presenter:

Abstract 4582 (Poster Board 61): Circulating tumor DNA (ctDNA) dynamics as early biomarkers of response to enfortumab vedotin plus pembrolizumab (EVP) in advanced urothelial carcinoma (aUC)
Presenter: MJ Moussa, M.D.

9 a.m.¨C12 p.m.

Abstract 5567 (Poster Board 233): Circulating tumor DNA to enhance detection of high-risk minimal residual disease in ovarian cancer relative to second look laparoscopy
Presenter: Helen Clark, M.D.

Abstract 5611 (Poster Board 277): Ultra-sensitive circulating tumor DNA (ctDNA) detection as a predictor of survival outcomes in endometrial cancer patients undergoing frontline treatment
Presenter:

Abstract TPS5635 (Poster Board 297b): A Phase 1, open-label, dose-finding, safety, tolerability and exploratory trial of the intraperitoneal THEO-260 in patients with high-grade serous or endometrioid ovarian cancer
Presenter: Helen Clark, M.D.

Abstract 6531 (Poster Board 324): Myelodysplasia-related mutation dynamics and outcomes in newly diagnosed (ND) acute myeloid leukemia (AML) treated with low-intensity therapy (LIT)
Presenter: Naszrin Arani, M.D.

Abstract 6542 (Poster Board 335): Cladribine (CLAD) + low-dose AraC (LDAC) + venetoclax (VEN) in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome: Real-world analysis from a large community-based oncology practice
Presenter: Janvi Bhatia

Abstract 6566 (Poster Board 359): Updated overall survival (OS) and long-term transfusion-independence from the Phase 3 COMMANDS trial in erythropoiesis-stimulating agent (ESA)-na?ve patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS)
Presenter:

Abstract 6570 (Poster Board 363): Whole genome sequencing to identify novel, clinically relevant findings missed by standard of care for patients with myelodysplastic syndrome
Presenter:

Abstract 6589 (Poster Board 382): Phase 2 trial of asciminib for newly diagnosed chronic myeloid leukemia
Presenter:

Abstract TPS6608 (Poster Board 369b): A Phase 3 study of olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress
Presenter:

Abstract 7044 (Poster Board 542): Pirtobrutinib in treatment-na?ve patients with CLL/SLL: Pooled results from BRUIN CLL-313 and BRUIN CLL-314
Presenter:

Abstract TOS7107 (Poster Board 601a): Phase 2 trial lisocabtagene maraleucel for minimal residual disease in patients with large B-cell lymphoma
Presenter:

Abstract 7549 (Poster Board 428): Duffy-null status and cytopenias following BCMA-directed CAR T therapy in multiple myeloma
Presenter: Christen Dillard, M.D.

Abstract 9022 (Poster Board 489): Career destination effects of receipt of the American Society of Clinical Oncology Young Investigator Award
Presenter:

Abstract 9040 (Poster Board 507): The role of coaching in enhancing clinical oncology academic performance
Presenter: Amanda Woods Herron, Ph.D.

Abstract 11177 (Poster Board 160): Prognostic value of circulating tumor DNA (ctDNA) for recurrence detection across solid tumors: A real-world meta-analysis
Presenter:

1:30¨C4:30 p.m.

Abstract 1022 (Poster Board 136): Identifying patients with human epidermal growth factor reception (HER2)-low and -ultralow breast cancer (BC): Use of digital, artificial intelligence (AI)-based computational algorithms to assist HER2 scoring by pathologists
Presenter: 

Abstract 1067 (Poster Board 181): Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus abemaciclib (ABE) in ER+/human epidermal growth factor receptor 2-negative (HER2?) advanced breast cancer (ABC): TACTIVE-U Phase 1b/2 results
Presenter: 

Abstract 1068 (Poster Board 182): Long-term safety results and adverse event (AE) management recommendations in patients with ER+/HER2? metastatic breast cancer (mBC) receiving prifetrastat, a first-in-class KAT6 inhibitor, at the recommended Phase 3 dose (RP3D) of 5 mg once-daily (QD)
Presenter: 

Abstract 1138 (Poster Board 252): Clinical and translational analysis of a Phase 1b/2 combination of atezolizumab, cobimetinib and eribulin (ACE) to demonstrate inflammatory and metabolic programs define divergent response states
Presenter: Elyse Lopez, M.D.

Abstract 1142 (Poster Board 256): Phase 2 study of olaparib plus ATR inhibitor ceralasertib in patients with metastatic breast cancer and germline BRCA1/2 pathogenic variants who progressed on prior PARP inhibitor therapy
Presenter: 

Abstract TPS 1155 (Poster Board 263a): ELECTRA: An open-label, multicenter Phase 1b/2 study of elacestrant in combination with abemaciclib patients with brain metastasis from ER+/HER- breast cancer
Presenter: 

Abstract TPS1166 (Poster Board 268b): IvoLoC: A Phase 2 trial of ivonescimab (IVO) in endocrine-refractory hormone receptor (HR)-positive or triple-negative (TN) metastatic invasive lobular carcinoma (mILC)
Presenter: 

Abstract 530 (Poster Board 15): Real-world treatment patterns and adherence to adjuvant abemaciclib among patients with early hormone receptor-positive (HR+) breast cancer (BC)
Presenter:

Abstract 587 (Poster Board 72): Distance recurrence-free survival in invasive lobular carcinoma (ILC) with isolated tumor cells: Does pN0(i+) behave like node-negative or node-positive disease?
Presenter:

Abstract 605 (Poster Board 90): Treatment patterns and oncologic outcomes in patients with triple-negative (TN) lobular breast cancer
Presenter: Laura Burns Amin, M.D.

Abstract 611 (Poster Board 96): DCE-MRI for assessment of pathologic complete response after completion of neoadjuvant therapy in triple-negative breast cancer patients
Presenter: Xiaofei Huo, M.D.

Abstract 614 (Poster Board 99): Response to neoadjuvant chemotherapy in both the breast and lymph nodes in patients with inflammatory breast cancer
Presenter: Megan McClanahan, M.D.

Abstract 629 (Poster Board 114): Real-world treatment patterns and mortality associated with GLP1-Ras n breast cancer patients
Presenter: 

Abstract 10524 (Poster Board 485): Time-restricted eating and metformin (TEAM) in invasive breast cancer or DCIS: A randomized, Phase 2b, window-of-opportunity presurgical trial
Presenter:

Abstract 11527 (Poster Board 317): A Phase 2 trial of cetuximab for patients with locally advanced/metastatic chordoma
Presenter:

Abstract 11571 (Poster Board 361): Adverse events and their management in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, after longer-term follow-up from the global Phase 3 MANEUVER trial
Presenter:

Abstract 11578 (Poster Board 368): Phase 1 trial of combination gemcitabine (gem) and nab-sirolimus (nab-S) in advanced leiomyosarcomas (LMS) or advanced soft-tissue sarcomas (STS) with TSC1/2 alterations: Preliminary results
Presenter:

Abstract TPS11595 (Poster Board 380b): SATURN-STS: Phase 2 study of neoadjuvant atezolizumab with doxorubicin, concurrent atezolizumab with pre-operative radiation therapy and adjuvant atezolizumab in patients with high-risk surgically resectable extremity and truncal soft tissue sarcoma
Presenter: